# Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

> **NCT01811368** · PHASE2 · UNKNOWN · sponsor: **Joseph Tuscano** · enrollment: 20 (estimated)

## Conditions studied

- Refractory Non Hodgkin Lymphoma
- Relapsed Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **BIOLOGICAL:** ibritumomab tiuxetan
- **BIOLOGICAL:** anti-thymocyte globulin
- **RADIATION:** total nodal irradiation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **DRUG:** cyclosporine
- **DRUG:** mycophenolate mofetil

## Key facts

- **NCT ID:** NCT01811368
- **Lead sponsor:** Joseph Tuscano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03-12
- **Primary completion:** 2023-04
- **Final completion:** 2023-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-11-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01811368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01811368, "Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT01811368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*